Plegridy is also named Pegylated interferon beta-1. It is a medicine a manufactured by Biogen. Plegridy is a medication used to treat multiple sclerosis. It is given by subcutaneous injection (under the skin) every 2 weeks.
In a typical year, 26 injections would be given of this medication.
Compared to placebo, the most likely side effects were injection site reactions, such as redness of the skin, pain at the injection site, itching, or muscle soreness. These occurred approximately 10% of the time in patients undergoing a study of this medication compared to placebo. Other adverse effects were not more likely with this medication compared to placebo.
Contraindications: Patients with a history of congestive heart failure or cardiomyopathy may not be good candidates for this medication. Autoimmune disorders such as autoimmune hepatitis have been reported with interferon medication.